July 12, 2020

The Niche

Knoepfler lab stem cell blog

Cellular Dynamics

4 min read

The big stem cell news already this week is the acquisition by Fujifilm of Cellular Dynamics International (CDI) for a whopping $307 million dollars or about $16.50 per CDI share. You can read the press release here. Update: The entity is now known as Fujifilm Cellular Dynamics. It was less than two years ago that CDI did its IPO with an initial offering of about $46 million. Fujifilm reportedly has a multibillion-dollar war chest for buying into the life sciences sector and a growing interest in regenerative …Read More

1 min read

I’ve added a fun and helpful new feature on the right side bar of the blog in the form of a stem cell biotech stock ticker. The ticker is for some of the most widely held stem and cellular medicine companies. A sample screen shot is shown in this post. Quite a few stem cell-related stocks could not be added to this ticker for various reasons including ACTC, Mesoblast, CUR, and others. Yahoo has limits on which stocks can be included based on company …Read More

3 min read

Stem cell technology is poised to wow the world with biomedical advances in the coming decades. Japan wants to lead the way, particularly with applications that focus on a relatively new kind of stem cells called induced pluripotent stem cells or iPS cells. Japanese researcher, Shinya Yamanaka, first reported production of iPS cells in 2006 in mice and in 2007 in humans. Japan has raced ahead of other countries and they appear to have the intellectual property rights and drive to do so. And …Read More

3 min read

Cellular Dynamics, the stem cell company founded by Dr. James Thomson, is filing for an IPO. Hat tip to David Jensen. The company, which will go under the stock symbol ICEL, is focused on iPS cell-produced products. They describe their portfolio as follows: Cellular Dynamics is developing and deploying a number of cell types derived from induced pluripotent stem (iPS) cells in additional to providing custom services to aid in life science research and drug discovery. If you recall, both Thomson and Dr. Shinya Yamanaka …Read More